Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 4;112(23):3823-3850.
doi: 10.1016/j.neuron.2024.10.013. Epub 2024 Nov 7.

Redox regulation, protein S-nitrosylation, and synapse loss in Alzheimer's and related dementias

Affiliations
Review

Redox regulation, protein S-nitrosylation, and synapse loss in Alzheimer's and related dementias

Chang-Ki Oh et al. Neuron. .

Abstract

Redox-mediated posttranslational modification, as exemplified by protein S-nitrosylation, modulates protein activity and function in both health and disease. Here, we review recent findings that show how normal aging, infection/inflammation, trauma, environmental toxins, and diseases associated with protein aggregation can each trigger excessive nitrosative stress, resulting in aberrant protein S-nitrosylation and hence dysfunctional protein networks. These redox reactions contribute to the etiology of multiple neurodegenerative disorders as well as systemic diseases. In the CNS, aberrant S-nitrosylation reactions of single proteins or, in many cases, interconnected networks of proteins lead to dysfunctional pathways affecting endoplasmic reticulum (ER) stress, inflammatory signaling, autophagy/mitophagy, the ubiquitin-proteasome system, transcriptional and enzymatic machinery, and mitochondrial metabolism. Aberrant protein S-nitrosylation and transnitrosylation (transfer of nitric oxide [NO]-related species from one protein to another) trigger protein aggregation, neuronal bioenergetic compromise, and microglial phagocytosis, all of which contribute to the synapse loss that underlies cognitive decline in Alzheimer's disease and related dementias.

Keywords: Alzheimer’s disease; Lewy body dementia; cognitive decline; neurodegenerative disorders; nitric oxide; protein S-nitrosylation; synapse loss; transnitrosylation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests S.A.L. discloses that he is an inventor on worldwide patents for the use of memantine and NitroSynapsin for neurodegenerative and neurodevelopmental disorders. Per Harvard University guidelines, he participates in a royalty-sharing agreement with his former institution, Boston Children’s Hospital/Harvard Medical School, which licensed the FDA-approved drug memantine (Namenda) to Forest Laboratories, Inc./Actavis/Allergan/AbbVie. S.A.L. is also a scientific founder of Adamas Pharmaceuticals, Inc. (now owned by Supernus Pharmaceuticals, Inc.), which developed or comarkets FDA-approved forms of memantine- or amantadine-containing drugs (NamendaXR, Namzaric, and GoCovri), and of EuMentis Therapeutics, Inc., which has licensed NitroSynapsin and related aminoadamantane nitrates from S.A.L. T.N. serves as a consultant to Dojindo Molecular Technologies, and S.A.L. serves on the Scientific Advisory Board of Point 6 Bio, Ltd.

References

    1. Arvanitakis Z, Shah RC, and Bennett DA (2019). Diagnosis and management of dementia: Review. JAMA 322, 1589–1599. 10.1001/jama.2019.4782. - DOI - PMC - PubMed
    1. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, and Katzman R (1991). Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572–580. 10.1002/ana.410300410. - DOI - PubMed
    1. DeKosky ST, and Scheff SW (1990). Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann. Neurol. 27, 457–464. 10.1002/ana.410270502. - DOI - PubMed
    1. Subramanian J, Savage JC, and Tremblay ME (2020). Synaptic loss in Alzheimer’s disease: Mechanistic insights provided by two-photon in vivo imaging of transgenic mouse models. Front. Cell. Neurosci. 14, 592607. 10.3389/fncel.2020.592607. - DOI - PMC - PubMed
    1. Griffiths J, and Grant SGN (2023). Synapse pathology in Alzheimer’s disease. Semin. Cell Dev. Biol. 139, 13–23. 10.1016/j.semcdb.2022.05.028. - DOI - PubMed

LinkOut - more resources